loader2
Partner With Us NRI

Shalby Ltd share Price Today

Company details

266.10
278.65
136.20
339.50
6M Return -9.91%
1Y Return 103.26%
Mkt Cap.(Cr) 2,999.98
Volume 170,657
Div Yield 0.43%
OI
-
OI Chg %
-
Volume 170,657

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Facilities company Shalby announced Q1FY24 results:

  • Consolidated Q1FY24:
    • Revenues of Rs 2,400 million, growth of 15% QoQ and 17% YoY
    • EBITDA of Rs 477 million, growth of 37% QoQ and 8% YoY
    • PBT of Rs 330 million, growth of 72% QoQ and 8% YoY
    • Basic EPS of Rs 1.94 during the quarter, growth of 50% QoQ
  • Standalone Q1FY24:
    • Revenues of Rs 2,164 million, growth of 18% QoQ and 20% YoY
    • EBITDA of Rs 497 million, growth of 36% QoQ and 16% YoY
    • PBT of Rs 400 million, growth of 51% QoQ and 22% YoY
    • EBITDA margin of 23% in Q1FY24 v/s 20% in Q4FY23 and 23.6% in Q1FY23
    • In-patient count (incl. Day Care) of 20,661, growth of 11% QoQ and 24% YoY
    • Total Surgery count of 8,183, growth of 25% QoQ and 14% YoY
    • Occupancy rate at 50% in Q1FY24 v/s 46% in Q4FY23 and 45% in Q1FY23
    • ARPOB during the quarter was 38,000, a growth of 9% QoQ and 8% YoY

Shanay Shah, President, Shalby, said: “I am very happy to report that this quarter reflected our best hospital business performance so far, across most financial and operating parameters, recording significant growth year-on-year and quarter-on-quarter. I am also proud to say that Shalby has achieved a landmark of 150,000 joint replacement surgeries (since inception) in Q1FY24 and with this we continue to maintain the leadership position in global volumes in the Orthopedics segment.

Our hospital business continued to grow high double-digit in the key metrics of In-Patient counts and surgery counts, growing by 24% and 14% respectively YoY in Q1FY24. Our hospital occupancy levels improved by 12% YoY and 8% QoQ and recorded a 50% occupancy rate in Q1FY24. ARPOB and ALOS were recorded at Rs 38,000 and 3.97 respectively in Q1FY24 vis-à-vis Rs 35,304 and 4.08 in the same quarter of the previous year.

Hospital revenue and EBITDA also grew by 18% and 36% QoQ respectively and 20% and 16% YoY respectively with a robust EBITDA margin of 23% in Q1FY24 v/s 20% in Q4 FY23. Our core specialties like Arthroplasty, Oncology, Cardiac Science, Orthopedic, Critical care & General Medicine, and Neurology contributed 85% to the revenues in Q1FY24.

Our Homecare business demonstrated a strong performance in Q1FY24, growing by 70% YoY and 30% QoQ. International revenue continued to grow in Q1FY24 from Q1FY23 whereby the majority of the patients came from East African countries. Shalby also takes pride in nurturing young talent through our Shalby Academy vertical with 290 students registered in the various healthcare programs during Q1FY24.

Realized Return on Capital Employed from hospital business recorded at 20% in Q1FY24 on an annualized basis. We have closed the quarter with a net cash balance of Rs 806 million at the group level and are well-positioned to fund our strategic growth plans. Shalby continued to add many milestones backed by clinical excellence and patient care. We remain committed to making a positive difference in people's lives."

 

Result PDF

View Other Company Results

Shalby Ltd shares SWOT Analysis

Strengths (11)

  • MACD Crossover Above Signal Line
  • Company with high TTM EPS Growth
  • Effectively using its capital to generate profit - RoCE improving in last 2 years

Weakness (1)

  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (4)

  • Results Screener: Stocks with upcoming results which are seeing positive shifts in share price
  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (0)

Data not found

Resistance and support

R1 282.2
R2 286.7
R3 294.8
Pivot

274.17

S1 269.7
S2 261.6
S3 257.1
EMA SMA
271.1
270.4
271.3
257.3
271.2
261.6
278.7
270.0
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
EQUITY INTELLIGENCE INDIA PRIVATE LIMITED Bulk Purchase 2023-03-28 117 610000 NSE
SHALBY LIMITED EMPLOYEES WELFARE TRUST Bulk Purchase 2022-05-30 107.5 700000 NSE
SHALBY MEDICOS TRUST Bulk Sell 2022-05-30 107.5 700000 NSE
Name Category Shares
VIKRAM INDRAJIT SHAH PROMOTER 7.38%
DARSHINI VIKRAM SHAH PROMOTER 2.79%
SHAH FAMILY TRUST THROUH DR. VIKRAM SHAH, TRUSTEE PROMOTER 34.73%
ZODIAC MEDIQUIP LIMITED PROMOTER 29.21%

OUR RESEARCH VIEW

Investment recommendation
Focused approach, long-drawn strategy to the fore…
Call Date
08 Apr 2024
Entry Price 266.00
Target Price 320.00
Duration
12 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Shalby Ltd Stocks COMPARISON

Financials( in Cr) Shalby Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Fortis Healthcare Ltd Global Health Ltd
Price 277.75 5,914.35 789.40 462.00 1,184.45
% Change 3.79 -0.93 -1.70 -1.48 -1.44
Mcap Cr 2,999.98 85,039.48 76,722.73 34,879.06 31,803.31
Revenue TTM Cr 804.92 16,612.50 4,831.37 6,537.06 2,694.25
Net Profit TTM Cr 67.68 887.50 1,103.51 632.98 326.08
PE TTM 36.90 108.28 72.57 59.43 66.45
1 Year Return 103.26 29.97 42.56 59.86 104.80
ROCE 10.35 14.16 13.85 7.51 16.49
ROE 7.50 15.04 16.12 6.79 16.13
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 927.69 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,248.28 -22,040.96
LAST 3M 102,638.29 -30,717.76
LAST 6M 167,920.74 50,623.85
LAST 12M 262,867.28 126,756.31
NSE Board Meetings Forthcomming

May 28, 2024 l NSE Board Meetings Forthcomming

Shalby Limited - Board Meeting

May 21, 2024 l NSE Announcement

Shalby to conduct board meeting

May 20, 2024 l BSE Announcement

Date Action Type Ratio
Aug 08, 2023 Dividend 12
Sep 19, 2022 Dividend 10

Shalby Ltd Information

Stock PE (TTM)
36.9
Promoter Holding
74.24%
Book Value
89.3004
ROCE
10.35%
ROE
7.5%
Description
  • Shalby Limited is an Ahmedabad-headquartered chain of multi-specialty hospitals and has a pan-India presence. It predominantly operates through 11 hospitals with an aggregate bed capacity of 2,012 beds. Out of these, 4 are located in Ahmedabad and 1 each at Vapi, Surat, Indore, Jabalpur, Mohali, Jaipur and Mumbai. Besides this, Shalby has 40 Outpatient Clinics spread across 35 cities of India and 7 Shalby Arthroplasty Centre of Excellence (SACE). It is expanding its footprint in western and central India. Shalby`s international footprint is spread across Africa, UAE, Bangladesh and Cambodia consisting of 6 outpatient clinics and 1 SACE in Africa, 2 SACE in the UAE and 1 outpatient clinic each in Bangladesh and Cambodia. Shalby is one of the leading multi-specialty chain of hospitals in India. The Hospitals are tertiary care hospitals, few of which also offer quaternary healthcare services to patients in various areas of specialisation such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, and renal transplantations. Led by Dr. Vikram Shah, an orthopaedic surgeon with more than 25 years of professional experience, The Hospital has grown from a single hospital to a chain of multi-specialty hospitals. Apart from a focus on orthopaedics, the hospitals provide advanced levels of care across various specialties such as neurology, cardiac care, critical care, oncology, and nephrology. The Hospitals, Krishna Shalby, SG Shalby, Shalby Indore and Shalby Jabalpur are accredited by the NABH. Further, Krishna Shalby and SG Shalby are also accredited by the NABL. Shalby Ltd was originally incorporated as a private limited company with the name `Shalby Hospital Private Limited` on August 30, 2004. Subsequently, The Company was converted to a public limited company and the name of the company was changed to `Shalby Hospital Public Limited` on May 15, 2006. The name of the Company was subsequently changed to Shalby Hospitals Limited on July 26, 2006. In 2007, the company established and commenced operations of its first multi-specialty hospital, SG Shalby, at Sarkhej Gandhinagar Highway in Ahmedabad. The name of the Company was changed to Shalby Limited on February 13, 2008. The company commenced a new hospital Shalby Vapi at Vapi in April 2012. The company commenced a new hospital Krishna Shalby in Ahmedabad in October 2012. The company commenced a new hospital Shalby Jabalpur at Jabalpur in Madhya Pradesh in March 2015. The company commenced a new hospital Shalby Indore at Indore in August 2015. In 2016, the company executed a memorandum of understanding with ZH Private Limited to manage and operate Zynova Shalby. During the year under review, the company executed an O&M agreement with Kamesh Hospital to commence operations of Shalby Mohali. In 2017, the company entered into an agreement with Bait Al Batterjee Medical Company LLC, Dubai, to provide outpatient orthopaedics and spine surgeries. On 22/05/2016 the company filed Draft Red Herring Prospectus and on 29/11/2017 filed Red Herring Prospectus with SEBI for raising Rs. 504.80 cr. The Issue dates were from 05/12/2017 to 07/12/2017 with Price Band of Rs. 245 to Rs. 248. The Issue got subscribed 2.27 times leading to its Issue Price being fixed at Rs. 248. The Shares got listed in BSE and NSE on 15/12/2017 at Rs. 237 which is 4.44% below Issue Price.On 27 March 2018, Shalby Limited announced that it has signed Memorandum of Understanding (MoU) to establish state- of- the art, Heart & Lung Transplant Centres, across all Shalby Units in India in association with Gleneagles Global Health City to provide comprehensive medical care facilities to patients across all Shalby units in India. This arrangement will facilitate patients and families residing in tier- II & tier-Ill cities and its catchment areas in a big way, by reducing their dependence on select metro cities for such life saving programs. This will enable Shalby and Gleneagles Global to expand their respective business verticals, adding more features, capabilities and boost patients footfalls. Shalby Limited (Shalby Multispecialty Hospitals), Ahmedabad signed a Memorandum of Understanding (MOU) with Sen Sok International University Hospital, Phnom Penh, Cambodia on April 12, 2018. Under the aegis of this MOU, to begin with, Shalby will be sending Specialists to Sen Sok Hospital for Orthopedic Specialty, which may be expanded to other specialties on mutual agreement, from time to time. Further, under the scope of the MOU, Shalby Academy, a unit of Shalby Limited, will allow nursing and Paramedic staff from Sen Sok International University Hospital to undergo various academic courses being run by Shalby Academy in India. Shalby Academy has been conducting various courses covering Paramedics, Hospital Management and specialized programs for doctors to excel in their careers. On 4 June 2018, Shalby Limited signed Memorandum of Understanding (MoU) with Berkeley Health Education P. Ltd, initiatives by promoter of Dabur Group, for conducting several programmes in Healthcare sector wherein Berkeley will organize the courses and Shalby will impart practical training at its various units across India. This Collaboration will benefit Nurses, Para Medical Staff and Doctors as several courses in different field of Healthcare will be conducted under this arrangement. On 1 September 2018, Shalby Limited informed the stock exchanges that Shalby Hospitals, Indore Unit has received the approval for Renal Transplant for a period of 5 years with effect from 6 July 2018 and Shalby Indore has successfully carried out one Renal Transplant, recently. This approval to our facility will facilitate patients from Madhya Pradesh and nearby states to reduce their dependence on select Metro cities for such life saving programs. On 20 September 2018, Shalby Hospitals, Jaipur performed a rare surgery on an 11 year old girl and removed an ovarian mass weighing 12.5 kg intact, to avoid spillage. On 24 September 2018, Shalby Limited informed the stock exchanges that credit rating agency ICRA Limited has upgraded the long-term ratings to [ICRA] A (pronounced as ICRA A) from [ICRA A-] (pronounced as ICRA A minus) on the term loans and fund based facilities aggregating to Rs 103.02 crore availed by the company. ICRA has also revised its outlook on the long-term rating to `Positive` from `Stable`.

Registered Address

Opp Karnawati Club, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat, 380015

Tel : 91-79-40203000
Email : companysecretary:shalby.in
Website : http://www.shalby.org
Registrar

KFin Techologies Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 540797
NSE Code : SHALBY
Book Closure Date (Month) : Aug
BSE Group : B
ISIN : INE597J01018

FAQ’s on Shalby Ltd Shares

You can buy Shalby Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Shalby Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 24, 2024 03:59 PM the closing price of Shalby Ltd was Rs.277.75.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 24, 2024 03:59 PM, the market cap of Shalby Ltd stood at Rs. 2,999.98.

The latest PE ratio of Shalby Ltd as of May 24, 2024 03:59 PM is 36.90

The latest PB ratio of Shalby Ltd as of May 24, 2024 03:59 PM is 0.32

The 52-week high of Shalby Ltd share price is Rs. 339.50 while the 52-week low is Rs. 136.20

According to analyst recommendations, Shalby Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app